Q1 EPS Estimates for Sutro Biopharma Raised by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued on Monday, March 17th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their previous estimate of ($0.82). HC Wainwright currently has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The business had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $10.44 million. During the same quarter last year, the firm earned ($1.78) earnings per share.

Several other equities analysts have also recently issued reports on the company. Wedbush cut Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $8.00 to $2.00 in a report on Friday, March 14th. Citizens Jmp cut Sutro Biopharma from an “outperform” rating to a “market perform” rating in a report on Friday, March 14th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a report on Wednesday, December 11th. Wells Fargo & Company reduced their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Finally, Bank of America cut Sutro Biopharma from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $11.00 to $1.00 in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $0.80 on Wednesday. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13. The company has a market cap of $65.64 million, a PE ratio of -0.49 and a beta of 1.22. The stock’s 50 day moving average price is $1.66 and its 200 day moving average price is $2.65.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new position in Sutro Biopharma in the third quarter valued at $2,852,000. BNP Paribas Financial Markets increased its stake in Sutro Biopharma by 1,195.1% in the third quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after purchasing an additional 76,152 shares during the last quarter. Rhumbline Advisers grew its position in Sutro Biopharma by 6.1% during the fourth quarter. Rhumbline Advisers now owns 126,698 shares of the company’s stock valued at $233,000 after acquiring an additional 7,320 shares during the period. Barclays PLC grew its position in Sutro Biopharma by 385.3% during the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock valued at $944,000 after acquiring an additional 216,757 shares during the period. Finally, Jane Street Group LLC grew its position in Sutro Biopharma by 30.7% during the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after acquiring an additional 25,416 shares during the period. 96.99% of the stock is currently owned by institutional investors and hedge funds.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.